Your browser doesn't support javascript.
loading
Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits.
Kim, Sung-Hee; Kim, Jiseon; Jang, Ji Yun; Noh, Hyuna; Park, Jisun; Jeong, Haengdueng; Jeon, Donghun; Uhm, Chanyang; Oh, Heeju; Cho, Kyungrae; Jeon, Yoon; On, Dain; Yoon, Suhyeon; Lim, Soo-Yeon; Kim, Sol Pin; Lee, Youn Woo; Jang, Hui Jeong; Park, In Ho; Oh, Jooyeon; Seo, Jung Seon; Kim, Jeong Jin; Seok, Sang-Hyuk; Lee, Yu Jin; Hong, Seung-Min; An, Se-Hee; Kim, Seo Yeon; Kim, Young Been; Hwang, Ji-Yeon; Lee, Hyo-Jung; Kim, Hong Bin; Choi, Kang-Seuk; Park, Jun Won; Seo, Jun-Young; Yun, Jun-Won; Shin, Jeon-Soo; Lee, Ho-Young; Kim, Kyoungmi; Lee, Daekee; Lee, Ho; Nam, Ki Taek; Seong, Je Kyung.
Afiliação
  • Kim SH; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim J; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • Jang JY; Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi, South Korea.
  • Noh H; College of Pharmacy, Dongguk University, Seoul, South Korea.
  • Park J; Korea Mouse Phenotyping Center, Seoul National University, Seoul, South Korea.
  • Jeong H; Department of Life Science, Ewha Womans University, Seoul, South Korea.
  • Jeon D; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • Uhm C; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • Oh H; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • Cho K; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • Jeon Y; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • On D; Division of Cancer Biology, Research Institute, National Cancer Center, Goyang, Gyeonggi, South Korea.
  • Yoon S; Korea Mouse Phenotyping Center, Seoul National University, Seoul, South Korea.
  • Lim SY; Laboratory of Developmental Biology and Genomics, Research Institute for Veterinary Science, and BK21 PLUS Program for Creative Veterinary Science Research, College of Veterinary Medicine, Seoul National University, Seoul, South Korea.
  • Kim SP; Korea Mouse Phenotyping Center, Seoul National University, Seoul, South Korea.
  • Lee YW; Korea Mouse Phenotyping Center, Seoul National University, Seoul, South Korea.
  • Jang HJ; Korea Mouse Phenotyping Center, Seoul National University, Seoul, South Korea.
  • Park IH; Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Oh J; Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Seo JS; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim JJ; Institute of Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, South Korea.
  • Seok SH; Department of Microbiology, Yonsei University College of Medicine, Seoul, South Korea.
  • Lee YJ; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • Hong SM; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • An SH; Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon, South Korea.
  • Kim SY; Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon, South Korea.
  • Kim YB; Laboratory of Avian Diseases, BK21 plus Program for Veterinary Science and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, South Korea.
  • Hwang JY; Laboratory of Avian Diseases, BK21 plus Program for Veterinary Science and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, South Korea.
  • Lee HJ; Preclinical Research Center, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Kim HB; Preclinical Research Center, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Choi KS; Preclinical Research Center, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Park JW; Department of Periodontology, Section of Dentistry, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Seo JY; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
  • Yun JW; Laboratory of Avian Diseases, BK21 plus Program for Veterinary Science and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul, South Korea.
  • Shin JS; Division of Biomedical Convergence, College of Biomedical Science, Kangwon National University, Chuncheon, South Korea.
  • Lee HY; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim K; Laboratory of Veterinary Toxicology, College of Veterinary Medicine, Seoul National University, Seoul, South Korea.
  • Lee D; Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
  • Lee H; Institute of Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, South Korea.
  • Nam KT; Department of Microbiology, Yonsei University College of Medicine, Seoul, South Korea.
  • Seong JK; Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Front Immunol ; 13: 1055811, 2022.
Article em En | MEDLINE | ID: mdl-36457995
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has been a global health concern since 2019. The viral spike protein infects the host by binding to angiotensin-converting enzyme 2 (ACE2) expressed on the cell surface, which is then processed by type II transmembrane serine protease. However, ACE2 does not react to SARS-CoV-2 in inbred wild-type mice, which poses a challenge for preclinical research with animal models, necessitating a human ACE2 (hACE2)-expressing transgenic mouse model. Cytokeratin 18 (K18) promoter-derived hACE2 transgenic mice [B6.Cg-Tg(K18-ACE2)2Prlmn/J] are widely used for research on SARS-CoV-1, MERS-CoV, and SARS-CoV-2. However, SARS-CoV-2 infection is lethal at ≥105 PFU and SARS-CoV-2 target cells are limited to type-1 alveolar pneumocytes in K18-hACE2 mice, making this model incompatible with infections in the human lung. Hence, we developed lung-specific SARS-CoV-2 infection mouse models with surfactant protein B (SFTPB) and secretoglobin family 1a member 1 (Scgb1a1) promoters. After inoculation of 105 PFU of SARS-CoV-2 to the K18-hACE2, SFTPB-hACE2, and SCGB1A1-hACE2 models, the peak viral titer was detected at 2 days post-infection and then gradually decreased. In K18-hACE2 mice, the body temperature decreased by approximately 10°C, body weight decreased by over 20%, and the survival rate was reduced. However, SFTPB-hACE2 and SCGB1A1-hACE2 mice showed minimal clinical signs after infection. The virus targeted type I pneumocytes in K18-hACE2 mice; type II pneumocytes in SFTPB-hACE2 mice; and club, goblet, and ciliated cells in SCGB1A1-hACE2 mice. A time-dependent increase in severe lung lesions was detected in K18-hACE2 mice, whereas mild lesions developed in SFTPB-hACE2 and SCGB1A1-hACE2 mice. Spleen, small intestine, and brain lesions developed in K18-hACE2 mice but not in SFTPB-hACE2 and SCGB1A1-hACE2 mice. These newly developed SFTPB-hACE2 and SCGB1A1-hACE2 mice should prove useful to expand research on hACE2-mediated respiratory viruses.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Enzima de Conversão de Angiotensina 2 / COVID-19 Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Coréia do Sul

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Enzima de Conversão de Angiotensina 2 / COVID-19 Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Coréia do Sul